Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Katriina Johanna Jalkanen
Observed names:
Jalkanen, Katriina,
Katriina J. Jalkanen,
Katriina Jalkanen,
Katriina Jalkanen Jalkanen
Institutions:
Helsinki University Hospital,
Hospital District of Helsinki and Uusimaa
Observed institutions:
The University of Texas MD Anderson Cancer Center,
Helsinki University Hospital,
Hospital District of Helsinki and Uusimaa
OpenAlex ID:
A5108897040
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
2024
·
Kjetil Taskén
, Soemeya F. Haj Mohammad
, et al.
·
Acta Oncologica
·
23
39 Safety profile of belzutifan monotherapy in patients with renal cell carcinoma: A pooled analysis of 4 clinical trials
2024
·
Toni K Choueiri
, Pooja Ghatalia
, et al.
·
The Oncologist
·
10
A national precision cancer medicine implementation initiative for Finland
2024
·
Katriina J. Jalkanen
, Erika Alanne
, et al.
·
Acta Oncologica
·
9
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes
2025
·
Tatiana V. Kudling
, Dmitrii Bychkov
, et al.
·
Cancer Gene Therapy
·
6
Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.
2024
·
Thomas Powles
, Laurence Albiges
, et al.
·
Journal of Clinical Oncology
·
6
Procedures of data merging in precision cancer medicine: the PRIME-ROSE project
2026
·
Henk Van der Pol
, Tina Kringelbach
, et al.
·
Acta Oncologica
·
4
PDF
Abstract CT188: BEHOLD-1: A Phase 1 Dose Escalation Study of GSK5733584, a B7-H4-Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors, Including Dose Expansion in Patients With Endometrial and Platinum-Resistant Ovarian Cancer
2025
·
William McKean
, Philippe L. Bedard
, et al.
·
Cancer Research
·
4
Dyslipidemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumors
2026
·
James Hugo Armstrong Clubb
, Santeri Artturi Pakola
, et al.
·
Molecular Therapy
·
3
PDF
Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors
2026
·
Elise Jirovec
, Katriina J. Jalkanen
, et al.
·
Molecular Therapy
·
2
Single point of entry to the European precision cancer medicine trial network PRIME-ROSE.
2024
·
Kjetil Tasken
, Gro Live Fagereng
, et al.
·
Journal of Clinical Oncology
·
2
PDF
First-in-human trial of the TEAD inhibitor ODM-212 in patients with advanced solid tumors (TEADES).
2026
·
Johann S. De Bono
, Yohann Loriot
, et al.
·
Journal of Clinical Oncology
·
1
Efficacy outcomes with belzutifan versus everolimus by baseline disease characteristics and burden subgroups in the phase 3 LITESPARK-005 study.
2025
·
Guillermo de Velasco
, Laurence Albiges
, et al.
·
Journal of Clinical Oncology
·
1
Intravenous delivery of oncolytic adenovirus TILT-123 results in systemic tumor transduction and accumulation of lymphocytes.
2024
·
Dafne Carolina Alves Quixabeira
, Elise Jirovec
, et al.
·
Journal of Clinical Oncology
·
1
Effects of Concomitant Medications on Clinical and Immunological Outcomes of Cancer Patients Treated With Oncolytic Adenoviruses
2026
·
Santeri A. Pakola
, Tatiana V. Kudling
, et al.
·
International Journal of Cancer
PDF
Antiviral humoral immunity as biomarker and effector in oncolytic adenovirus TILT-123 therapy
2026
·
Victor Arias
, James H Clubb
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
BEHOLD-1 and -2: phase 1/2 randomized studies evaluating the B7 homolog 4 protein-targeted antibody-drug conjugate mocertatug rezetecan in patients with solid tumors, including endometrial and ovarian cancers
2026
·
Stephanie Lheureux
, Diane Provencher
, et al.
·
International Journal of Gynecological Cancer
PRIME-ROSE: A blueprint for implementing precision cancer medicine in Europe.
2026
·
Gro Live Fagereng
, Henk van der Pol
, et al.
·
Journal of Clinical Oncology
Abstract LB419: Dose escalation and expansion of nivolumab plus relatlimab (NIVO + RELA) in solid tumors in RELATIVITY 020 Parts A-C
2026
·
Paolo A. Ascierto
, Carlo Gomez-Roca
, et al.
·
Cancer Research
Antibiotic treatment indicates shorter survival in patients with immunotherapy for metastatic kidney cancer
2026
·
Elisa Kankkunen
, Kaisa Sunela Sunela
, et al.
·
Acta Oncologica
PDF
Transcriptomic & single-cell translational analyses on gynecologic cancer patients receiving MEK-inhibitors in the FINPROVE trial
2026
·
Anni Suoknuuti
, Silja Kauppila
, et al.
·
International Journal of Gynecological Cancer
Procedure for pooling clinical outcome data from DRUP-like clinical trials using the OMOP model.
2025
·
Henk van der Pol
, Tina Kringelbach
, et al.
·
Journal of Clinical Oncology
Randomized dose evaluation of nivolumab + relatlimab (NIVO + RELA) in patients (pts) with advanced melanoma: Results from RELATIVITY-020.
2025
·
Georgina V. Long
, Stéphane Dalle
, et al.
·
Journal of Clinical Oncology
PDF
In-depth Characterization of the Safety Profile of Belzutifan Monotherapy in Patients With Renal Cell Carcinoma: a Pooled Analysis of Four Clinical Trials
2025
·
Eric Jonasch
, Pooja Ghatalia
, et al.
·
Urologic Oncology Seminars and Original Investigations
Show more works
View as search
Works count:
31
Citation count:
72
H-index:
5
I10-index:
2
Year
Topic
Type
